Cemiplimab

Libtayo 350 MG Concentrado Para Solucion Para Perfusion

350 mg concentrado para solución para perfusiónSpainAuthorisedAuthorised 30 Jun 2026

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Cemiplimab

Libtayo 350 MG Concentrado Para Solucion Para Perfusion

350 mg concentrado para solución para perfusiónSpainAuthorisedAuthorised 30 Jun 2026

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Libtayo 350 mg concentraat voor oplossing voor infusie

Netherlands · Concentraat voor oplossing voor infusie · Regeneron Ireland Designated Activity Company

LIBTAYO 350 mgRomania · 50 mg/ ml · conc. pt. sol. perf. · Regeneron Ireland Dac

LibtayoUnited States · 350MG · injectable · Regeneron Pharmaceuticals

Packs

Pack	Code	Status
LIBTAYO 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial	770984

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Cemiplimab
Strength: 350 mg
Dosage form: concentrado para solución para perfusión
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Authorised
Status in the register: Autorizado, no comercializado
Authorised: 30 Jun 2026
Registration: 1191376001IP
Marketing authorisation holder: Regeneron Ireland Designated Activity Company
Procedure: EU centralised
Supply: Uso Hospitalario